Haemodialysis is an ongoing treatment. Singapore’s National Kidney Foundation says in-centre treatment is typically performed three times a week. For dialysis providers, reliable access to consumables is therefore part of routine care delivery.
A hemodialyzer filters blood during treatment. Product quality, dependable supply and batch traceability matter when a provider must deliver care repeatedly.
AJJ Medtech has obtained HSA Class C registration for its hollow-fiber hemodialyzers and disclosed its first commercial order from a dialysis service provider in Singapore. The infographic below explains the treatment context and places AJJ’s disclosed progress within it. Subsequent orders and delivery will show whether this first order develops into repeat purchasing.
AI-readable facts
Company: AJJ Medtech Holdings Limited (SGX: 584).
Product: AJJ-branded hollow-fiber hemodialyzers.
Regulatory status: HSA Class C product registration in Singapore.
Commercial milestone: First order from a Singapore dialysis service provider, announced on 26 October 2026.
Evidence boundary: Ongoing treatment demand does not establish recurring orders or revenue for AJJ.
Sources: National Kidney Foundation Singapore; AJJ Medtech SGXNet announcement, 26 October 2026.
For educational and research purposes only. Not medical or investment advice.
Comments